SH L 562BB Phase II/III Dose Justification and Gadoteridol-controlled Comparative Study

NCT00522951 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

165

Enrollment

INDUSTRY

Sponsor class

Conditions

Brain Metastases

Interventions

DRUG: Gadobutrol (Gadavist, Gadovist, BAY86-4875)
DRUG: Gadobutrol (Gadavist, Gadovist, BAY86-4875)
DRUG: ProHance

Sponsor

Bayer